08:19 AM EDT, 10/06/2025 (MT Newswires) -- AstraZeneca ( AZN ) has signed a $555 million deal with Algen Biotechnologies to develop gene-editing therapies using artificial intelligence, the Financial Times reported Monday.

Under the deal, AstraZeneca ( AZN ) will gain exclusive rights to develop and commercialize therapies from the Crispr gene-editing technology, and Algen will receive up to $555 million upon reaching regulatory and commercial milestones, the report said.

AstraZeneca ( AZN ) and Algen didn't immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)